Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Hynes

Showing results (211-220 of 275) with videos related to

Pageof 28
Sort By:
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 5, 2003
Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigenMylène Dorvillius, Vèronique Garambois, Didier Pourquier, et al.
Oncogene|June 22, 1999
NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathwaysJ M Daly, M A Olayioye, A M Wong, et al.
Investigational New Drugs|May 1, 1990
Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group studyE H Kraut, J J Crowley, M R Grever, et al.
British Journal of Cancer|December 18, 2001
Internalisation enhances photo-induced cytotoxicity of monoclonal antibody-phthalocyanine conjugatesM Carcenac, M Dorvillius, V Garambois, et al.
Oncogene|December 17, 2009
Copine-III interacts with ErbB2 and promotes tumor cell migrationC Heinrich, C Keller, A Boulay, et al.
Nature Communications|July 14, 2016
Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer modelsAlessia Bottos, Dagmar Gotthardt, Jason W Gill, et al.
Oncogene|April 27, 2018
Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibitionAlbana Gattelli, Martín E García Solá, Tim C Roloff, et al.
Gynecologic Oncology|August 1, 1992
Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group studyH H Gallion, P Y Liu, D E Alberts, et al.
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1992
[Interferon-gamma suppresses expression of the HER-2 oncogene in ovarian cancer cells]C Marth, E Müller-Holzner, A G Zeimet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trialC A Russell, S J Green, J O'Sullivan, et al.
Pageof 28

Showing results (211-220 of 275) with videos related to

Sort By:
Pageof 28
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 5, 2003
Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigenMylène Dorvillius, Vèronique Garambois, Didier Pourquier, et al.
Oncogene|June 22, 1999
NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathwaysJ M Daly, M A Olayioye, A M Wong, et al.
Investigational New Drugs|May 1, 1990
Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group studyE H Kraut, J J Crowley, M R Grever, et al.
British Journal of Cancer|December 18, 2001
Internalisation enhances photo-induced cytotoxicity of monoclonal antibody-phthalocyanine conjugatesM Carcenac, M Dorvillius, V Garambois, et al.
Oncogene|December 17, 2009
Copine-III interacts with ErbB2 and promotes tumor cell migrationC Heinrich, C Keller, A Boulay, et al.
Nature Communications|July 14, 2016
Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer modelsAlessia Bottos, Dagmar Gotthardt, Jason W Gill, et al.
Oncogene|April 27, 2018
Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibitionAlbana Gattelli, Martín E García Solá, Tim C Roloff, et al.
Gynecologic Oncology|August 1, 1992
Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group studyH H Gallion, P Y Liu, D E Alberts, et al.
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1992
[Interferon-gamma suppresses expression of the HER-2 oncogene in ovarian cancer cells]C Marth, E Müller-Holzner, A G Zeimet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trialC A Russell, S J Green, J O'Sullivan, et al.
Pageof 28